A Multiple Dose Combination Study to Evaluate the Safety and Tolerability of Tirzepatide and LY3841136 in Overweight and Obese Participants
Latest Information Update: 29 Jan 2025
At a glance
- Drugs Eloralintide (Primary) ; Tirzepatide (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
Most Recent Events
- 24 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 25 Nov 2024 Planned number of patients changed from 80 to 96.
- 25 Nov 2024 Planned End Date changed from 1 Mar 2025 to 1 Oct 2025.